Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages.

Antibodies / immunology Antibodies, Viral / immunology Antigens, Viral / immunology Cross Reactions / immunology Genetic Variation Humans Immunity, Humoral Immunization Lassa Fever / immunology Lassa virus / immunology Nigeria / epidemiology Nucleoproteins Recombinant Proteins Sierra Leone / epidemiology Survivors

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
29 09 2020
Historique:
received: 12 04 2020
accepted: 31 08 2020
entrez: 30 9 2020
pubmed: 1 10 2020
medline: 26 1 2021
Statut: epublish

Résumé

Lassa virus (LASV) is the causative agent of Lassa fever, an often-fatal hemorrhagic disease that is endemic in West Africa. Seven genetically distinct LASV lineages have been identified. As part of CEPI's (Coalition for Epidemic Preparedness Innovations) Lassa vaccine development program, we assessed the potential of the human immune system to mount cross-reactive and cross-protective humoral immune responses to antigens from the most prevalent LASV lineages, which are lineages II and III in Nigeria and lineage IV in Sierra Leone. IgG and IgM present in the blood of Lassa fever survivors from Nigeria or Sierra Leone exhibited substantial cross-reactivity for binding to LASV nucleoprotein and two engineered (linked and prefusion) versions of the glycoproteins (GP) of lineages II-IV. There was less cross-reactivity for the Zinc protein. Serum or plasma from Nigerian Lassa fever survivors neutralized LASV pseudoviruses expressing lineage II GP better than they neutralized lineage III or IV GP expressing pseudoviruses. Sierra Leonean survivors did not exhibit a lineage bias. Neutralization titres determined using LASV pseudovirus assays showed significant correlation with titres determined by plaque reduction with infectious LASV. These studies provide guidance for comparison of humoral immunity to LASV of distinct lineages following natural infection or immunization.

Identifiants

DOI: 10.1038/s41598-020-72539-w PMID: 32994446 PMC: PMC7525497
pubmed: 32994446
doi: 10.1038/s41598-020-72539-w
pii: 10.1038/s41598-020-72539-w
pmc: PMC7525497
doi:

Substances chimiques

Antibodies 0
Antibodies, Viral 0
Antigens, Viral 0
Nucleoproteins 0
Recombinant Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

16030

Subventions

Organisme : NIAID NIH HHS
ID : R43 AI138836
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI132223
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI142790
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI132244
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI151812
Pays : United States
Organisme : NHGRI NIH HHS
ID : U54 HG007480
Pays : United States

Références

Akpede, G. O. et al. Caseload and case fatality of Lassa fever in Nigeria, 2001–2018: A specialist center’s experience and its implications. Front. Public Health 7, 170. https://doi.org/10.3389/fpubh.2019.00170 (2019).
doi: 10.3389/fpubh.2019.00170 pubmed: 31294014 pmcid: 6603170
Ilori, E. A. et al. Epidemiologic and clinical features of Lassa fever outbreak in Nigeria, January 1–May 6, 2018. Emerg. Infect. Dis. 25, 1066–1074. https://doi.org/10.3201/eid2506.181035 (2019).
doi: 10.3201/eid2506.181035 pubmed: 31107222 pmcid: 6537738
Shaffer, J. G. et al. Lassa fever in post-conflict Sierra Leone. PLoS Negl. Trop. Dis. 8, e2748. https://doi.org/10.1371/journal.pntd.0002748 (2014).
doi: 10.1371/journal.pntd.0002748 pubmed: 24651047 pmcid: 3961205
McCormick, J. B. Epidemiology and control of Lassa fever. Curr. Top Microbiol. Immunol. 134, 69–78 (1987).
pubmed: 3581899
Arnold, R. B. & Gary, G. W. A neutralization test survey for Lassa fever activity in Lassa, Nigeria. Trans. R. Soc. Trop. Med. Hyg. 71, 152–154 (1977).
doi: 10.1016/0035-9203(77)90085-2
Monath, T. P., Newhouse, V. F., Kemp, G. E., Setzer, H. W. & Cacciapuoti, A. Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone. Science 185, 263–265 (1974).
doi: 10.1126/science.185.4147.263
Lecompte, E. et al. Mastomys natalensis and Lassa fever, West Africa. Emerg. Infect. Dis. 12, 1971–1974 (2006).
doi: 10.3201/eid1212.060812
Olayemi, A. et al. New hosts of the Lassa virus. Sci. Rep. 6, 25280. https://doi.org/10.1038/srep25280 (2016).
doi: 10.1038/srep25280 pubmed: 27140942 pmcid: 4853722
Yadouleton, A. et al. Lassa virus in pygmy mice, Benin, West Africa, 2016–2017. Emerg. Infect. Dis. https://doi.org/10.3201/eid2510.180523 (2019).
doi: 10.3201/eid2510.180523 pubmed: 31365854 pmcid: 6759236
Okokhere, P. et al. Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: A retrospective, observational cohort study. Lancet. Infect. Dis 18, 684–695. https://doi.org/10.1016/s1473-3099(18)30121-x (2018).
doi: 10.1016/s1473-3099(18)30121-x pubmed: 29523497 pmcid: 5984133
Duvignaud, A. et al. Lassa fever clinical course and setting a standard of care for future randomized trials: A protocol for a cohort study of Lassa-infected patients in Nigeria (LASCOPE). Travel. Med. Infect. Dis. https://doi.org/10.1016/j.tmaid.2020.101557 (2020).
doi: 10.1016/j.tmaid.2020.101557 pubmed: 31978611
Eberhardt, K. A. et al. Ribavirin for the treatment of Lassa fever: A systematic review and meta-analysis. Int. J. Infect. Dis. https://doi.org/10.1016/j.ijid.2019.07.015 (2019).
doi: 10.1016/j.ijid.2019.07.015 pubmed: 31357056
Mehand, M. S., Al-Shorbaji, F., Millett, P. & Murgue, B. The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts. Antiviral Res. 159, 63–67. https://doi.org/10.1016/j.antiviral.2018.09.009 (2018).
doi: 10.1016/j.antiviral.2018.09.009 pubmed: 30261226 pmcid: 7113760
Bernasconi, V. et al. Developing vaccines against epidemic-prone emerging infectious diseases. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 63, 65–73. https://doi.org/10.1007/s00103-019-03061-2 (2020).
doi: 10.1007/s00103-019-03061-2 pubmed: 31776599
Gouglas, D., Christodoulou, M., Plotkin, S. A. & Hatchett, R. CEPI: Driving progress towards epidemic preparedness and response. Epidemiol. Rev. https://doi.org/10.1093/epirev/mxz012 (2019).
doi: 10.1093/epirev/mxz012 pubmed: 31673694 pmcid: 7108492
Coalition for Epidemic Preparedness Innovations. Preparing for Lassa vaccine trials with targeted epidemiology studies. https://cepi.net/get_involved/cfps/ (2019).
Abudurexiti, A. et al. Taxonomy of the order Bunyavirales: Update 2019. Arch. Virol. 164, 1949–1965. https://doi.org/10.1007/s00705-019-04253-6 (2019).
doi: 10.1007/s00705-019-04253-6 pubmed: 31065850 pmcid: 6641860
Oldstone, M. B. Arenaviruses. II. The molecular pathogenesis of arenavirus infections. Introduction. Curr. Top Microbiol. Immunol. 263, 5–12 (2002).
Oldstone, M. B. Arenaviruses. I. The epidemiology molecular and cell biology of arenaviruses Introduction. Curr. Top Microbiol. Immunol. 262, 5–12 (2002).
Ehichioya, D. U. et al. Phylogeography of Lassa virus in Nigeria. J. Virol. https://doi.org/10.1128/jvi.00929-19 (2019).
doi: 10.1128/jvi.00929-19 pubmed: 31413134 pmcid: 6803284
Andersen, K. G. et al. Clinical sequencing uncovers origins and evolution of Lassa virus. Cell 162, 738–750. https://doi.org/10.1016/j.cell.2015.07.020 (2015).
doi: 10.1016/j.cell.2015.07.020 pubmed: 26276630 pmcid: 4537774
Bowen, M. D. et al. Genetic diversity among Lassa virus strains. J.. Virol. 74, 6992–7004 (2000).
doi: 10.1128/JVI.74.15.6992-7004.2000
Siddle, K. J. et al. Genomic analysis of Lassa virus during an increase in cases in Nigeria in 2018. N. Engl. J. Med. 379, 1745–1753. https://doi.org/10.1056/NEJMoa1804498 (2018).
doi: 10.1056/NEJMoa1804498 pubmed: 30332564 pmcid: 6181183
Kafetzopoulou, L. E. et al. Metagenomic sequencing at the epicenter of the Nigeria 2018 Lassa fever outbreak. Science 363, 74–77. https://doi.org/10.1126/science.aau9343 (2019).
doi: 10.1126/science.aau9343 pubmed: 30606844 pmcid: 6855379
Buckley, S. M. & Casals, J. Lassa fever, a new virus disease of man from West Africa. 3. Isolation and characterization of the virus. Am. J. Trop. Med. Hyg. 19, 680–691 (1970).
doi: 10.4269/ajtmh.1970.19.680
Olayemi, A. et al. Arenavirus diversity and phylogeography of Mastomys natalensis rodents, Nigeria. Emerg. Infect. Dis. 22, 694–697. https://doi.org/10.3201/eid2204.150155 (2016).
doi: 10.3201/eid2204.150155 pubmed: 26982388 pmcid: 4806934
Ehichioya, D. U. et al. Current molecular epidemiology of Lassa virus in Nigeria. J. Clin. Microbiol. 49, 1157–1161. https://doi.org/10.1128/jcm.01891-10 (2011).
doi: 10.1128/jcm.01891-10 pubmed: 21191050 pmcid: 3067713
Oloniniyi, O. K. et al. Genetic characterization of Lassa virus strains isolated from 2012 to 2016 in southeastern Nigeria. PLoS Negl. Trop. Dis. 12, e0006971. https://doi.org/10.1371/journal.pntd.0006971 (2018).
doi: 10.1371/journal.pntd.0006971 pubmed: 30500827 pmcid: 6267959
Wiley, M. R. et al. Lassa virus circulating in Liberia: A retrospective genomic characterisation. Lancet. Infect. Dis https://doi.org/10.1016/s1473-3099(19)30486-4 (2019).
doi: 10.1016/s1473-3099(19)30486-4 pubmed: 31588039
Safronetz, D. et al. Geographic distribution and genetic characterization of Lassa virus in sub-Saharan Mali. PLoS Negl. Trop. Dis. 7, e2582. https://doi.org/10.1371/journal.pntd.0002582 (2013).
doi: 10.1371/journal.pntd.0002582 pubmed: 24340119 pmcid: 3855028
Manning, J. T., Forrester, N. & Paessler, S. Lassa virus isolates from Mali and the Ivory Coast represent an emerging fifth lineage. Front. Microbiol. 6, 1037. https://doi.org/10.3389/fmicb.2015.01037 (2015).
doi: 10.3389/fmicb.2015.01037 pubmed: 26483768 pmcid: 4589679
Whitmer, S. L. M. et al. New lineage of Lassa virus, Togo, 2016. Emerg. Infect. Dis. 24, 599–602. https://doi.org/10.3201/eid2403.171905 (2018).
doi: 10.3201/eid2403.171905 pubmed: 29460758 pmcid: 5823357
Emperador, D. M., Yimer, S. A., Mazzola, L. T., Norheim, G. & Kelly-Cirino, C. Diagnostic applications for Lassa fever in limited-resource settings. BMJ Glob. Health 4, e001119. https://doi.org/10.1136/bmjgh-2018-001119 (2019).
doi: 10.1136/bmjgh-2018-001119 pubmed: 30899576 pmcid: 6407552
Emmerich, P., Gunther, S. & Schmitz, H. Strain-specific antibody response to Lassa virus in the local population of west Africa. J. Clin. Virol. 42, 40–44. https://doi.org/10.1016/j.jcv.2007.11.019 (2008).
doi: 10.1016/j.jcv.2007.11.019 pubmed: 18164653
Botten, J. et al. HLA-A2-restricted protection against lethal lymphocytic choriomeningitis. J. Virol. 81, 2307–2317. https://doi.org/10.1128/jvi.02063-06 (2007).
doi: 10.1128/jvi.02063-06 pubmed: 17166907
Lukashevich, I. S., Paessler, S. & de la Torre, J. C. Lassa virus diversity and feasibility for universal prophylactic vaccine. F1000Research https://doi.org/10.12688/f1000research.16989.1 (2019).
doi: 10.12688/f1000research.16989.1 pubmed: 30774934 pmcid: 6357994
Warner, B. M., Safronetz, D. & Stein, D. R. Current research for a vaccine against Lassa hemorrhagic fever virus. Drug Des. Dev. Ther. 12, 2519–2527. https://doi.org/10.2147/dddt.S147276 (2018).
doi: 10.2147/dddt.S147276
Salami, K., Gouglas, D., Schmaljohn, C., Saville, M. & Tornieporth, N. A review of Lassa fever vaccine candidates. Curr. Opin. Virol. 37, 105–111. https://doi.org/10.1016/j.coviro.2019.07.006 (2019).
doi: 10.1016/j.coviro.2019.07.006 pubmed: 31472333
Branco, L. M. et al. Bacterial-based systems for expression and purification of recombinant Lassa virus proteins of immunological relevance. Virol. J. 5, 74. https://doi.org/10.1186/1743-422x-5-74 (2008).
doi: 10.1186/1743-422x-5-74 pubmed: 18538016 pmcid: 2435526
Grove, J. N. et al. Capacity building permitting comprehensive monitoring of a severe case of Lassa hemorrhagic fever in Sierra Leone with a positive outcome: case report. Virol. J. 8, 314. https://doi.org/10.1186/1743-422x-8-314 (2011).
doi: 10.1186/1743-422x-8-314 pubmed: 21689444 pmcid: 3283910
Branco, L. M. et al. Emerging trends in Lassa fever: Redefining the role of immunoglobulin M and inflammation in diagnosing acute infection. Virol. J. 8, 478. https://doi.org/10.1186/1743-422x-8-478 (2011).
doi: 10.1186/1743-422x-8-478 pubmed: 22023795 pmcid: 3223505
Boisen, M. L. et al. Field validation of the ReEBOV antigen rapid test for point-of-care diagnosis of ebola virus infection. J. Infect. Dis. https://doi.org/10.1093/infdis/jiw261 (2016).
doi: 10.1093/infdis/jiw261 pubmed: 27587634 pmcid: 5050482
Branco, L. M. et al. Lassa hemorrhagic fever in a late term pregnancy from northern Sierra Leone with a positive maternal outcome: case report. Virol. J. 8, 404. https://doi.org/10.1186/1743-422x-8-404 (2011).
doi: 10.1186/1743-422x-8-404 pubmed: 21843352 pmcid: 3177908
Safronetz, D. et al. Detection of Lassa virus Mali. Emerg. Infect. Dis. 16, 1123–1126. https://doi.org/10.3201/eid1607.100146 (2010).
doi: 10.3201/eid1607.100146 pubmed: 20587185 pmcid: 3321918
Ogunro, B. N. et al. Detection of antibody and antigen for Lassa virus nucleoprotein in monkeys from southern Nigeria. J. Epidemiol. Glob. Health 9, 125–127. https://doi.org/10.2991/jegh.k.190421.001 (2019).
doi: 10.2991/jegh.k.190421.001 pubmed: 31241870 pmcid: 7310747
Cross, R. W. et al. Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death. J. Clin. Invest. 130, 539–551. https://doi.org/10.1172/jci131958 (2020).
doi: 10.1172/jci131958 pubmed: 31820871
Cashman, K. A. et al. A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever. Hum. Vacc. Immunother. 13, 2902–2911. https://doi.org/10.1080/21645515.2017.1356500 (2017).
doi: 10.1080/21645515.2017.1356500
Robinson, J. E. et al. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat. Commun. 7, 11544. https://doi.org/10.1038/ncomms11544 (2016).
doi: 10.1038/ncomms11544 pubmed: 27161536 pmcid: 4866400
Hastie, K. M. et al. Structural basis for antibody-mediated neutralization of Lassa virus. Science 356, 923–928. https://doi.org/10.1126/science.aam7260 (2017).
doi: 10.1126/science.aam7260 pubmed: 28572385 pmcid: 6007842
Hastie, K. M. et al. Convergent structures illuminate features for germline antibody binding and pan-Lassa virus neutralization. Cell 178, 1004-1015.e1014. https://doi.org/10.1016/j.cell.2019.07.020 (2019).
doi: 10.1016/j.cell.2019.07.020 pubmed: 31398326 pmcid: 6814208
Boisen, M. L. et al. Field evaluation of a Pan-Lassa rapid diagnostic test during the 2018 Nigerian Lassa fever outbreak. Sci. Rep. 10, 8724. https://doi.org/10.1038/s41598-020-65736-0 (2020).
doi: 10.1038/s41598-020-65736-0 pubmed: 32457420 pmcid: 7250850
Lewis, R. M., Cosgriff, T. M., Griffin, B. Y., Rhoderick, J. & Jahrling, P. B. Immune serum increases arenavirus replication in monocytes. J. Gen. Virol. 69(Pt 7), 1735–1739 (1988).
doi: 10.1099/0022-1317-69-7-1735
Clegg, J. C. & Lloyd, G. Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever. Lancet 2, 186–188 (1987).
doi: 10.1016/S0140-6736(87)90767-7
Sakabe, S. et al. Identification of common CD8+ T cell epitopes from Lassa fever survivors in Nigeria and Sierra Leone. J. Virol. https://doi.org/10.1128/jvi.00153-20 (2020).
doi: 10.1128/jvi.00153-20 pubmed: 32269122 pmcid: 7307091
Sullivan, B. M. et al. High crossreactivity of human T cell responses between Lassa virus lineages. PLoS Pathog. 16, e1008352. https://doi.org/10.1371/journal.ppat.1008352 (2020).
doi: 10.1371/journal.ppat.1008352 pubmed: 32142546 pmcid: 7080273
Prescott, J. B. et al. Immunobiology of Ebola and Lassa virus infections. Nat. Rev. Immunol. 17, 195–207. https://doi.org/10.1038/nri.2016.138 (2017).
doi: 10.1038/nri.2016.138 pubmed: 28111475
McCormick, J. B. & Fisher-Hoch, S. P. Lassa fever. Curr. Top. Microbiol. Immunol. 262, 75–109 (2002).
pubmed: 11987809
Jahrling, P. B., Peters, C. J. & Stephen, E. L. Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys. J. Infect. Dis. 149, 420–427 (1984).
doi: 10.1093/infdis/149.3.420
Jahrling, P. B. & Peters, C. J. Passive antibody therapy of Lassa fever in cynomolgus monkeys: Importance of neutralizing antibody and Lassa virus strain. Infect. Immun. 44, 528–533 (1984).
doi: 10.1128/IAI.44.2.528-533.1984
Cross, R. W. et al. Antibody therapy for Lassa fever. Curr. Opin. Virol. 37, 97–104. https://doi.org/10.1016/j.coviro.2019.07.003 (2019).
doi: 10.1016/j.coviro.2019.07.003 pubmed: 31401518
Mire, C. E. et al. Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nat. Med. 23, 1146–1149. https://doi.org/10.1038/nm.4396 (2017).
doi: 10.1038/nm.4396 pubmed: 28869611 pmcid: 5719877
Cross, R. W. et al. Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies. Antiviral Res. 133, 218–222. https://doi.org/10.1016/j.antiviral.2016.08.012 (2016).
doi: 10.1016/j.antiviral.2016.08.012 pubmed: 27531367 pmcid: 5032844
Hastie, K. M. & Saphire, E. O. Lassa virus glycoprotein: Stopping a moving target. Curr. Opin. Virol. https://doi.org/10.1016/j.coviro.2018.05.002 (2018).
doi: 10.1016/j.coviro.2018.05.002 pubmed: 29843991 pmcid: 6193841
McCormick, J. B., Mitchell, S. W., Kiley, M. P., Ruo, S. & Fisher-Hoch, S. P. Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys. J. Med. Virol. 37, 1–7 (1992).
doi: 10.1002/jmv.1890370102
Safronetz, D. et al. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses. PLoS Negl. Trop. Dis. 9, e0003736. https://doi.org/10.1371/journal.pntd.0003736 (2015).
doi: 10.1371/journal.pntd.0003736 pubmed: 25884628 pmcid: 4401668
Zalgen Labs. ReLASV® Pan-Lassa NP IgG/IgM ELISA Kit. https://www.zalgen.com/wp-content/uploads/2019/05/PI-10004.pdf .
Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307–312. https://doi.org/10.1038/nature01470 (2003).
doi: 10.1038/nature01470 pubmed: 12646921
Jahrling, P. B., Smith, S., Hesse, R. A. & Rhoderick, J. B. Pathogenesis of Lassa virus infection in guinea pigs. Infect. Immun. 37, 771–778 (1982).
doi: 10.1128/IAI.37.2.771-778.1982

Auteurs

Megan L Heinrich (ML)

Zalgen Labs, LCC, Germantown, MD, USA.

Matthew L Boisen (ML)

Zalgen Labs, LCC, Germantown, MD, USA.

Diana K S Nelson (DKS)

Zalgen Labs, LCC, Germantown, MD, USA.

Duane J Bush (DJ)

Zalgen Labs, LCC, Germantown, MD, USA.

Robert W Cross (RW)

Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Galveston National Laboratory, Galveston, TX, USA.

Anatoliy P Koval (AP)

Zalgen Labs, LCC, Germantown, MD, USA.

Andrew R Hoffmann (AR)

Department of Microbiology and Immunology, School of Medicine, Tulane University, 1430 Tulane Avenue, New Orleans, LA, JBJ56870118, USA.

Brandon J Beddingfield (BJ)

Department of Microbiology and Immunology, School of Medicine, Tulane University, 1430 Tulane Avenue, New Orleans, LA, JBJ56870118, USA.

Kathryn M Hastie (KM)

La Jolla Institute for Immunology, La Jolla, CA, 92037, USA.

Megan M Rowland (MM)

Zalgen Labs, LCC, Germantown, MD, USA.

Irina Aimukanova (I)

Zalgen Labs, LCC, Germantown, MD, USA.

Sophia Koval (S)

Zalgen Labs, LCC, Germantown, MD, USA.

Raju Lathigra (R)

Zalgen Labs, LCC, Germantown, MD, USA.

Viktoriya Borisevich (V)

Galveston National Laboratory, Galveston, TX, USA.
Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.

Mambu Momoh (M)

Eastern Polytechnic Institute, Kenema, Sierra Leone.
Viral Hemorrhagic Fever Program, Kenema Government Hospital, Kenema, Sierra Leone.
Ministry of Health and Sanitation, Freetown, Sierra Leone.

John Demby Sandi (JD)

Viral Hemorrhagic Fever Program, Kenema Government Hospital, Kenema, Sierra Leone.

Augustine Goba (A)

Viral Hemorrhagic Fever Program, Kenema Government Hospital, Kenema, Sierra Leone.

Lkponmwosa Odia (L)

Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.

Francis Baimba (F)

Viral Hemorrhagic Fever Program, Kenema Government Hospital, Kenema, Sierra Leone.

John O Aiyepada (JO)

Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.

Benevolence Ebo (B)

Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.

Philomena Eromon (P)

The African Center of Excellence for Genomics of Infectious Diseases, Redeemer's University, Ede, Osun State, Nigeria.
Department of Biological Sciences, College of Natural Sciences, Redeemer's University, Ede, Osun State, Nigeria.

Chinedu Ugwu (C)

The African Center of Excellence for Genomics of Infectious Diseases, Redeemer's University, Ede, Osun State, Nigeria.
Department of Biological Sciences, College of Natural Sciences, Redeemer's University, Ede, Osun State, Nigeria.

Onikepe Folarin (O)

The African Center of Excellence for Genomics of Infectious Diseases, Redeemer's University, Ede, Osun State, Nigeria.
Department of Biological Sciences, College of Natural Sciences, Redeemer's University, Ede, Osun State, Nigeria.

Testimony Olumade (T)

The African Center of Excellence for Genomics of Infectious Diseases, Redeemer's University, Ede, Osun State, Nigeria.
Department of Biological Sciences, College of Natural Sciences, Redeemer's University, Ede, Osun State, Nigeria.

MacDonald N Onyechi (MN)

Federal Medical Center Owo, Owo, Nigeria.

Johnson Etafo (J)

Federal Medical Center Owo, Owo, Nigeria.

Rashidat Adeyemi (R)

Ahmadu Bello University, Zaria, Nigeria.

Elijah E Ella (EE)

Ahmadu Bello University, Zaria, Nigeria.

Maryam Aminu (M)

Ahmadu Bello University, Zaria, Nigeria.

Simji S Gomerep (SS)

University Teaching Hospital, Jos, Nigeria.

Matthew Afam Eke (MA)

Federal Medical Center, Abakaliki, Nigeria.

Olusola Ogunsanya (O)

University of Ibadan, Ibadan, Nigeria.

George O Akpede (GO)

Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.
Department of Paediatrics, Irrua Specialist Teaching Hospital, Irrua, Nigeria.
Department ofPaediatrics, College of Medicine, Ambrose Alli University, Ekpoma, Nigeria.

Danny O Asogun (DO)

Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.
Department of Community Medicine, Irrua Specialist Teaching Hospital, Irrua, Nigeria.

Sylvanus A Okogbenin (SA)

Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.
Department of Obstetrics and Gynaecology, Irrua Specialist Teaching Hospital, Irrua, Nigeria.

Peter O Okokhere (PO)

Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.
The Department of Medicine, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.
The Department of Medicine, Faculty of Clinical Sciences, Ambrose Alli University, Ekpoma, Edo State, Nigeria.

Johan Holst (J)

CEPI (Coalition for Epidemic Preparedness Innovations), Oslo, Norway.

Jeffrey G Shaffer (JG)

Department of Biostatistics and Bioinformatics, Tulane School of Public Health and Tropical Medicine, New Orleans, LA, USA.

John S Schieffelin (JS)

Sections of Infectious Disease, Departments of Pediatrics and Internal Medicine, School of Medicine, Tulane University, New Orleans, LA, USA.

Thomas W Geisbert (TW)

Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Galveston National Laboratory, Galveston, TX, USA.

Erica Ollmann Saphire (EO)

La Jolla Institute for Immunology, La Jolla, CA, 92037, USA.

Christian T Happi (CT)

The African Center of Excellence for Genomics of Infectious Diseases, Redeemer's University, Ede, Osun State, Nigeria. happic@run.edu.ng.
Department of Biological Sciences, College of Natural Sciences, Redeemer's University, Ede, Osun State, Nigeria. happic@run.edu.ng.
Department of Molecular Biology and Genomics, Center of Excellence for Genomics of Infectious Diseases (ACEGID), Redeemer's University, Ede, Osun State, Nigeria. happic@run.edu.ng.

Donald S Grant (DS)

Viral Hemorrhagic Fever Program, Kenema Government Hospital, Kenema, Sierra Leone. donkumfel@yahoo.co.uk.
Ministry of Health and Sanitation, Freetown, Sierra Leone. donkumfel@yahoo.co.uk.

Robert F Garry (RF)

Zalgen Labs, LCC, Germantown, MD, USA. rfgarry@tulane.edu.
Department of Microbiology and Immunology, School of Medicine, Tulane University, 1430 Tulane Avenue, New Orleans, LA, JBJ56870118, USA. rfgarry@tulane.edu.

Luis M Branco (LM)

Zalgen Labs, LCC, Germantown, MD, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Antibodies from Sierra Leonean and Nigerian...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps antiviraux › Antibodies from Sierra Leonean and Nigerian...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Antigènes viraux › Antibodies from Sierra Leonean and Nigerian...
questionsmedicales.fr › Phénomènes du système immunitaire › Réaction antigène-anticorps › Réactions croisées › Antibodies from Sierra Leonean and Nigerian...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Antibodies from Sierra Leonean and Nigerian...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Antibodies from Sierra Leonean and Nigerian...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Immunité acquise › Immunité humorale › Antibodies from Sierra Leonean and Nigerian...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Pratiques en santé publique › Prévention primaire › Immunisation › Antibodies from Sierra Leonean and Nigerian...
questionsmedicales.fr › Infection › Maladies virales › Infections à virus à ARN › Fièvres hémorragiques virales › Fièvre de Lassa › Antibodies from Sierra Leonean and Nigerian...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN de polarité négative › Arenaviridae › Arenavirus › Arénavirus de l'Ancien Monde › Virus de Lassa › Antibodies from Sierra Leonean and Nigerian...
questionsmedicales.fr › Régions géographiques › Afrique › Afrique subsaharienne › Afrique de l'Ouest › Nigeria › Antibodies from Sierra Leonean and Nigerian...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Nucléoprotéines › Antibodies from Sierra Leonean and Nigerian...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines recombinantes › Antibodies from Sierra Leonean and Nigerian...
questionsmedicales.fr › Régions géographiques › Afrique › Afrique subsaharienne › Afrique de l'Ouest › Sierra Leone › Antibodies from Sierra Leonean and Nigerian...
questionsmedicales.fr › Personnes › Survivants › Antibodies from Sierra Leonean and Nigerian...